奈达铂联合多西他赛治疗老年晚期非小细胞肺癌的疗效观察

Observation on efficacy of nedaplatin combined with docetaxel in the treatment of advanced non-small cell lung cancer in senile patients

目的探讨奈达铂联合多西他赛用于治疗老年晚期非小细胞肺癌的临床疗效,为临床上的进一步诊治提供一定的参考依据。方法 68例晚期非小细胞肺癌老年患者作为研究对象,随机将患者分为实验组和对照组,每组34例。给予两组患者不同的化疗方法 ,实验组患者采用奈达铂联合多西他赛的化疗方式,对照组患者采用顺铂联合多西他赛的化疗方式。比较两组患者临床治疗效果和不良反应的发生情况。结果实验组患者治疗总有效率(64.7%)明显高于对照组(38.2%),差异具有统计学意义(P<0.05)。实验组患者癌胚抗原(CEA)水平为(22.34±13.24)μg/L,对照组患者的CEA水平为(40.52±14.32)μg/L,实验组的CEA水平明显低于对照组患者,差异具有统计学意义(P<0.05)。实验组患者各不良反应发生率均明显低于对照组患者,差异有统计学意义(P<0.05)。结论奈达铂联合多西他赛的化疗方式对老年晚期非小细胞肺癌患者具有明显的临床疗效,能够有效的减少患者不良反应发生情况,值得临床上的进一步使用和推广。

Objective To investigate the clinical efficacy of nedaplatin combined with docetaxel in the treatment of advanced non-small cell lung cancer in senile patients, and provide reference for further diagnosis and treatment in clinic. Methods A total of 68 senile patients withadvanced non-small cell lung cancer as study subjects were randomty divided into experimental group and control group, with 34 cases in each group. Both groups received different chemotherapy modes. The experimental group received chemotherapy modes of nedaplatin and docetaxel, and the control group received chemotherapy modes of cisplatin and docetaxel. Comparison were made on clinical treatment effect and occurrence of adverse reactions between two groups. Results The experimental group had obviously higher total treatment effective rate （64.7%） than the control group （38.2%）, and the difference was statistically significant （P〈0.05）. The experimental group had carcino- embryonic antigen （CEA） level as （22.34 ± 13.24） μg/L, which was （40.52 ±14.32） μg/L in the control group. The experimental group had obviously lower CEA level than the control group, and the difference was statistically significant （P〈0.05）. The experimental group had obviously lower incidence of adverse reactions than the control group, and the statistically significant difference （P〈0.05）. Conclusion Chemotherapy mode of nedaplatin and docetaxel contains obvious clinical efficacy for senile patients with non-small cell lung cancer, and it can effectively reduce the occurrence of adverse reactions. It is worthy of further use and promotion in clinic.